<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00852813</url>
  </required_header>
  <id_info>
    <org_study_id>AXOS 002</org_study_id>
    <nct_id>NCT00852813</nct_id>
  </id_info>
  <brief_title>Tolerance and Prebiotic Activity of Arabinoxylan-Oligosaccharides in Healthy Subjects</brief_title>
  <official_title>Tolerance and Prebiotic Activity of Arabinoxylan-Oligosaccharides in Healthy Subjects: a Randomized, Placebo-Controlled Cross-Over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the tolerance of a higher dose of
      arabinoxylan-oligosaccharides (AXOS) and their prebiotic activity in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>arabinoxylan-oligosaccharides (AXOS)</intervention_name>
    <description>intake period: 3 weeks, 10 g/day</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy

          -  18-45 years

          -  regular eating pattern

        Exclusion Criteria:

          -  gastrointestinal complaints

          -  antibiotic intake

          -  medication influencing gut transit or microbiota

          -  abdominal surgery

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin Verbeke, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Katholieke Universiteit Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gastrointestinal Research, Laboratory Digestion and Absorption</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Cloetens L, De Preter V, Swennen K, Broekaert WF, Courtin CM, Delcour JA, Rutgeerts P, Verbeke K. Dose-response effect of arabinoxylooligosaccharides on gastrointestinal motility and on colonic bacterial metabolism in healthy volunteers. J Am Coll Nutr. 2008 Aug;27(4):512-8.</citation>
    <PMID>18978172</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2009</study_first_submitted>
  <study_first_submitted_qc>February 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2009</study_first_posted>
  <last_update_submitted>February 26, 2009</last_update_submitted>
  <last_update_submitted_qc>February 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Kristin verbeke</name_title>
    <organization>Katholieke Universiteit Leuven</organization>
  </responsible_party>
  <keyword>tolerance</keyword>
  <keyword>prebiotic</keyword>
  <keyword>gastrointestinal effects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

